Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Timothy Hill

Physical Medicine & Rehabilitation Bend, OR Medical Doctor

NPI 1891790382 CMS profile 176791

2200 Ne Neff Rd, Ste. 200, Bend, OR 97701

Open in the dashboard

General payments

$302

13 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Timothy Hill of Bend, OR is reported in the CMS Open Payments database as having received $302 across 13 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $84 4
2022 General $93 2
2021 General $32 2
2019 General $93 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Hill
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Timothy Hill were reported at $0. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Timothy Hill Physical Medicine & Rehabilitation median Middle half National median
2019 $93 $133 $45–$390 $163
2020 $0 $88 $29–$272 $114
2021 $32 $116 $33–$360 $132
2022 $93 $123 $40–$378 $149
2023 $84 $131 $43–$396 $160
2024 $0 $141 $45–$409 $164
2025 $0 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Medtronic, Inc. $106 3 payments
  2. AbbVie, Inc. $47 2 payments
  3. Pfizer Inc. $38 2 payments
  4. Boston Scientific Corporation $27 1 payment
  5. Biohaven Pharmaceuticals, Inc. $20 1 payment
  6. Nalu Medical, Inc. $20 1 payment
  7. Medtronic USA, Inc. $17 1 payment
  8. Piramal Critical Care $17 1 payment
  9. Scilex Pharmaceuticals Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $302 13 payments
Products named General payments · program years 2019–2023
  1. SYNCHROMEDII $74 1 payment
  2. UBRELVY $47 2 payments
  3. EMBEDA $38 2 payments
  4. FLECTOR PATCH $38 2 payments
  5. SPECTRA WAVEWRITER $27 1 payment
  6. QULIPTA $25 1 payment
  7. AQUAMANTYS(TM) $20 1 payment
  8. NURTEC ODT $20 1 payment
  9. Nalu Neurostimulation System $20 1 payment
  10. LYRICA $19 1 payment
  11. Other $108 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,821

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$54,362

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

35.4%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 28 $21,137
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 390 $8,561
Gabapentin Generic 241 $5,201
Duloxetine Hcl Generic 163 $4,503
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 170 $3,103
Oxycodone Hcl Generic 140 $2,182
Pregabalin Generic 66 $1,545
Morphine Sulfate Er Morphine Sulfate Brand 44 $1,361
Tizanidine Hcl Generic 99 $1,278
Celecoxib Generic 13 $954

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 82 billing codes

Paid by Medicare

$157,166

Of which drugs: $1,547

Medicare patients

815

Average age 73

Services billed

11,665

476 women, 339 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 66%
Ischemic heart disease 27%
Depression 24%
Osteoporosis 21%
Diabetes 19%
Atrial fibrillation 14%
Chronic kidney disease 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 181 9,304 $945
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 29 196 $136
Injection, methylprednisolone acetate, 40 mg J1030 Office 28 29 $127

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

13 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record